Canopy的动态

Who's heading to AVBCC? Be sure to catch Canopy's Lavi Kwiatkowsky and Michael Kolodziej, MD, who are co-chairs of this year's event and participating in 11 panels, including: - Care Management: If It's So Good, Why Aren't We Doing It? - Bispecific Antibodies: What Are the Barriers to Community Adoption? - Reimbursement: Get Ready for 2025 We hope to see you during this industry-leading event on value-based cancer care! Learn more: https://www.canopycare.us/ Association for Value-Based Cancer Care

Did your organization apply for the reopened Enhancing Oncology Model (EOM)? In a recent Canopy webinar, thought leaders from CMS and community oncology shared helpful insights and strategies for success in the EOM and other value-based programs. Catch the full discussion to learn more: https://lnkd.in/ekfjd6V4

At Canopy, we collaborate with oncology care teams to optimize end-to-end triage processes for continuous care. One way we do this is through Operator and Triage Pathways. Operator Pathways help non-clinical staff identify and escalate urgent patient issues reported during phone calls, while Triage Pathways empower clinical staff to quickly resolve these issues through standardized decision support. Together, these pathways help streamline timely, high-quality care. Read here to learn more: https://lnkd.in/eAwEm9m9

Canopy's Lavi Kwiatkowsky, Founder & CEO, and Michael Kolodziej, MD, Chief Medical Officer, are among the 2024 AVBCC Co-Chairs and will take part in several panels during this year's program. We hope to see you during this industry-leading event on value-based cancer care! Learn more: https://lnkd.in/ehnFn2we

ICYMI! Canopy recently announced platform-wide support for bispecific antibodies: https://lnkd.in/e-ri3jWT “Patients receiving these treatments require vigilant monitoring and nuanced management to ensure safety. Canopy’s technology plays a crucial role in keeping patients safe when they’re away from the clinic, especially when administering bispecific antibodies and CAR-T in the outpatient setting.” —James Essell, MD, Medical Director of the Center for Cancer and Cellular Therapy at Oncology Hematology Care and The Jewish Hospital, and Chair for Cellular Therapy at Sarah Cannon Research Institute Canopy's Continuous Care Platform supports care teams in safely administering these therapies in the outpatient setting through ePRO-based remote monitoring, smart triage algorithms, and decision-support pathways for CRS and ICANs. Read our official press release to learn more: https://lnkd.in/e-ri3jWT

What an incredible week at the ONCare Leadership Summit! Canopy was honored to sponsor, and our Chief Medical Officer, Michael Kolodziej, MD, took part in three insightful panels: ? When the 800 lb. Gorilla Comes Knocking: Hospital-Practice Affiliation Basics ? Negotiating With & Managing Hospital Relationships ? Understanding Payers: A Primer Thank you to ONCare Alliance for a stellar event and for all you do to ensure people with cancer achieve the best possible outcomes. Curious how Canopy helps care teams deliver continuous care? Learn more here: www.canopycare.us

Thank you to IT Digest for featuring our launch of platform-wide support for bispecific antibodies. Read below to learn how Canopy helps oncology practices safely integrate these novel therapies into the outpatient setting.

Attending ONCare Leadership Summit? Be sure to stop by the Canopy booth to meet our team and join Michael Kolodziej, MD, Canopy's Chief Medical Officer, as he participates in the following panels: ? When the 800 lb. Gorilla Comes Knocking: Hospital-Practice Affiliation Basics ? Negotiating With & Managing Hospital Relationships ? Understanding Payers: A Primer Learn more about Canopy's approach to continuous care and find time to meet here: www.canopycare.us ONCare Alliance

?? Announced Today! ?? We’re excited to launch platform-wide support for bispecific antibodies, including ePRO-based remote monitoring, smart triage algorithms, and decision-support pathways for CRS and ICANs. “Patients receiving these treatments require vigilant monitoring and nuanced management to ensure safety. Canopy’s technology plays a crucial role in keeping patients safe when they’re away from the clinic, especially when administering bispecific antibodies and CAR-T in the outpatient setting.” —James Essell, MD, Medical Director of the Center for Cancer and Cellular Therapy at Oncology Hematology Care and The Jewish Hospital, and Chair for Cellular Therapy at Sarah Cannon Research Institute Read our official press release to learn more: https://lnkd.in/e-ri3jWT